KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Buildings: 2010-2017

  • Regeneron Pharmaceuticals' Buildings rose 12.77% to $1.4 billion in Q4 2017 from the same period last year, while for Dec 2017 it was $1.4 billion, marking a year-over-year increase of 12.77%. This contributed to the annual value of $1.4 billion for FY2017, which is 12.77% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Buildings of $1.4 billion as of Q4 2017, which was up 12.77% from $1.3 billion recorded in Q4 2016.
  • In the past 5 years, Regeneron Pharmaceuticals' Buildings ranged from a high of $1.4 billion in Q4 2017 and a low of $343.4 million during Q4 2013.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Buildings value was $1.3 billion (recorded in 2016), while the average stood at $1.2 billion.
  • Data for Regeneron Pharmaceuticals' Buildings shows a peak YoY surged of 90.61% (in 2015) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Buildings (Quarterly) stood at $343.4 million in 2013, then climbed by 16.20% to $399.0 million in 2014, then spiked by 90.61% to $760.5 million in 2015, then spiked by 68.08% to $1.3 billion in 2016, then rose by 12.77% to $1.4 billion in 2017.
  • Its Buildings was $1.4 billion in Q4 2017, compared to $1.3 billion in Q4 2016 and $760.5 million in Q4 2015.